Resistance mechanisms to BRAF inhibition identified by single circulating tumor cell and cell-free tumor DNA molecular profiling in BRAF-mutant non-small-cell lung cancer
Literature
Read More
NeoGenomics Schedules its First Quarter 2021 Earnings Release for May 5, 2021
Press Release
Read More
Early plasma circulating tumor DNA (ctDNA) changes predict response to first-line pembrolizumab-based therapy in non-small cell lung cancer (NSCLC)
Literature
Read More
NeoGenomics and Elevation Oncology Announce Collaboration to Expand Genomic Testing for NRG1 Fusions Across Solid Tumors in Support of the Phase 2 CRESTONE Study
Press Release
Read More
NeoGenomics To Participate In The Virtual Raymond James 42nd Annual Institutional Investors Conference
Press Release
Read More